Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PONTIAC: trastuzumab deruxtecan versus CDK4/6 inhibitor plus endocrine therapy in first-line HR-positive HER2-low/ultralow non-luminal advanced breast cancer
NL-OMON60596Phase 2Recruiting
- Sponsor
- MEDSIR
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by MEDSIR. Started Jun 2026; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60596.